Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$144.95 - $152.29 $43.9 Million - $46.1 Million
302,714 Added 241.94%
427,832 $64.7 Million
Q2 2022

Aug 12, 2022

SELL
$83.14 - $145.99 $15.6 Million - $27.5 Million
-188,157 Reduced 60.06%
125,118 $18.2 Million
Q1 2022

May 16, 2022

BUY
$110.08 - $142.92 $4.17 Million - $5.42 Million
37,914 Added 13.77%
313,275 $37.1 Million
Q4 2021

Feb 08, 2022

BUY
$99.73 - $148.48 $3.07 Million - $4.58 Million
30,824 Added 12.61%
275,361 $37.9 Million
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $608,817 - $855,546
6,159 Added 2.58%
244,537 $34 Million
Q2 2021

Sep 13, 2021

BUY
$65.78 - $105.02 $15.7 Million - $25 Million
238,378 New
238,378 $23.1 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.